Quantitative assessment of the association between DNMT3B-579G&gt;T polymorphism and cancer risk

Xia, Zhen; Duan, Fujiao; Chang, Jing; Guo, Zhihua; Nie, Changfu; Song, Chunhua

doi:10.3233/cbm-150512

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For rs1569686, we consider it as a protective factor for gastric carcinogenesis and similar results were discovered in head and neck cancer, lung cancer and colorectal cancer (Duan et al, 2015, Zhang et al, 2015, Xia et al, 2015, Zhu et al, 2012). However, another study argued it was associated with poor prognosis in GC cases (Wang et al, 2015a).…”

Section: Discussionsupporting

confidence: 54%

“…Previous meta-analysis studies primarily evaluated associations between a few SNPs and cancers without classification, such as GC (Zhu et al, 2015, Duan et al, 2015, Liu et al, 2015, Zhang et al, 2015, Xia et al, 2015). The major strengths of our study was its comprehensive and systematic focus on GC and SNPs from three main types of DNMTs , 17 SNPs in total.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

DNMT1 , DNMT3A and DNMT3B Polymorphisms Associated With Gastric Cancer Risk: A Systematic Review and Meta-analysis

Liu

et al. 2016

EBioMedicine

View full text Add to dashboard Cite

BackgroundIncreasing studies showed that abnormal changes in single nucleotide polymorphisms (SNPs) of DNMTs (DNMT1, DNMT3A and DNMT3B) were associated with occurrence or decrease of various tumors. However, the associations between DNMTs variations and gastric cancer (GC) risk were still conflicting. We aimed to assess the effect of DNMTs polymorphisms on the susceptibility to GC.MethodsFirstly, we did a meta-analysis for 7 SNPs (rs16999593, rs2228611, rs8101866 in DNMT1, rs1550117, rs13420827 in DNMT3A, rs1569686, rs2424913 in DNMT3B). Four genetic models (homozygote, heterozygote, dominant and recessive model) were used. Moreover, a meta-sensitivity and subgroup analysis was performed to clarify heterogeneity source. Lastly, 17 SNPs that couldn't be meta-analyzed were presented in a systematic review.Findings20 studies were included, 13 studies could be meta-analyzed and 7 ones could not. Firstly, a meta-analysis on 13 studies (3959 GC cases and 5992 controls) for 7 SNPs showed that GC risk increased in rs16999593 (heterozygote model: OR 1.36, 95%CI 1.14–1.61; dominant model: OR 1.36, 95%CI 1.15–1.60) and rs1550117 (homozygote model: OR 2.03, 95%CI 1.38–3.00; dominant model: OR 1.20, 95%CI 1.01–1.42; recessive model: OR 1.96, 95%CI 1.33–2.89) but decreased in rs1569686 (dominant model: OR 0.74, 95%CI 0.61–0.90). The remaining SNPs were not found associated with GC risk. Furthermore, the subgroup analysis indicated that for rs1550117 and rs1569686, the significant associations were particularly found in people from Chinese Jiangsu province (rs1550117, OR 1.77, 95%CI 1.25–2.51; rs1569686, OR 0.48, 95%CI 0.36–0.64) and that PCR-RFLP was a sensitive method to discover significant associations (rs1550117, OR 1.77, 95%CI 1.25–2.51; rs1569686, OR 0.49, 95%CI 0.37–0.65). Lastly, a systematic review on 7 studies for 17 SNPs suggested that rs36012910, rs7560488 and rs6087990 might have a potential effect on GC initiation.ConclusionThis meta-analysis demonstrated that rs16999593 and rs1550117 could contribute to GC risk and that rs1569686 might be a protective factor against gastric carcinogenesis. By using these SNPs as biomarkers, it is feasible to estimate the risk of acquiring GC and thus formulate timely preventive strategy.

show abstract

Section: Discussionsupporting

confidence: 54%

Section: Discussionmentioning

confidence: 99%

DNMT1 , DNMT3A and DNMT3B Polymorphisms Associated With Gastric Cancer Risk: A Systematic Review and Meta-analysis

Liu

et al. 2016

EBioMedicine

View full text Add to dashboard Cite

show abstract

“…For example, polymorphisms determining upregulation of gene transcription have been associated with an increased risk of developing lung cancer and head and neck carcinoma ( Shen et al, 2002 ; Liu et al, 2008 ). Based on meta-analysis data, a polymorphism in a DNMT3B regulative region has also been associated with reduced risk of cancer ( Zhu et al, 2012 ) but this point is still debated ( Xia et al, 2015 ).…”

Section: Alteration Of Dnmt3b Function In Human Diseasementioning

confidence: 99%

DNMT3B Functions: Novel Insights From Human Disease

Gagliardi

Strazzullo

Matarazzo

2018

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

DNA methylation plays important roles in gene expression regulation and chromatin structure. Its proper establishment and maintenance are essential for mammalian development and cellular differentiation. DNMT3B is the major de novo DNA methyltransferase expressed and active during the early stage of embryonic development, including implantation. In addition to its well-known role to methylate centromeric, pericentromeric, and subtelomeric repeats, recent observations suggest that DNMT3B acts as the main enzyme methylating intragenic regions of active genes. Although largely studied, much remains unknown regarding how these specific patterns of de novo CpG methylation are established in mammalian cells, and which are the rules governing DNMT3B recruitment and activity. Latest evidence indicates that DNMT3B recruitment is regulated by numerous mechanisms including chromatin modifications, transcription levels, non-coding RNAs, and the presence of DNA-binding factors. DNA methylation abnormalities are a common mark of human diseases involving chromosomal and genomic instabilities, such as inherited disease and cancer. The autosomal recessive Immunodeficiency, Centromeric instability and Facial anomalies syndrome, type I (ICF-1), is associated to hypomorphic mutations in DNMT3B gene, while its altered expression has been correlated with the development of tumors. In both cases, this implies that abnormal DNA hypomethylation and hypermethylation patterns affect gene expression and genomic architecture contributing to the pathological states. We will provide an overview of the most recent research aimed at deciphering the molecular mechanisms by which DNMT3B abnormalities are associated with the onset and progression of these pathologies.

show abstract

“…Moreover, we determined that the heterozygote GT genotype and the dominant model (GG vs. GT+TT) were associated with a reduced risk of colorectal cancer. Similarly, in a meta-analysis of 18 studies, Xia et al, (2015) reported that the heterozygous GT genotype and the dominant model (GT+TT) were associated with a reduced risk of the disease among the Asian population. A similar conclusion was presented by Zhu et al, (2012) who analyzed 11 studies (including 3513 cases and 3714 controls) to find different results in Asian and European populations.…”

Section: Discussionmentioning

confidence: 92%

Investigation of the DNMT3B –579 G>T Promoter Polymorphism in Patients with Colorectal Cancer in an Azerbaijani Population

Bayramov

Aslanov³

et al. 2022

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective:The main aim of the present study was to determine the clinical significance of the DNA methyltransferase 3B (DNMT3B) gene -579 G>T polymorphism in colorectal cancer (CRC) patients. Methods: A total of 140 patients with CRC and 164 healthy individuals were included in the study. According to the manufacturer's instructions, DNA was isolated from blood, and genotypes were determined on agarose gel by the PCR-RFLP method. Genotype confirmation was performed using Sanger sequencing in randomly selected samples. Results: When comparing the case and control groups, heterozygous GT (OR=0.53; 95% CI=0.32-0.88), under the dominant model (OR=0.53; 95% CI=0.33-0.87), and the mutant T allele (OR=0.71; 95% CI=0.51-0.98) were statistically associated with a reduced risk of CRC. However, when the age, pathological tumor grade and stage, smoking habit, and alcohol consumption were compared, no significant relationship was determined (P>0.05). Furthermore, among males, heterozygous GT was associated with a reduced risk of CRC (OR=0.40; 95% CI=0.19-0.84). Conclusion: Our study highlighted that the -579 G>T polymorphism of the DNMT3B gene plays a protective role against CRC development.

show abstract

Quantitative assessment of the association between DNMT3B-579G>T polymorphism and cancer risk

Abstract: DNMT3B-579G>T polymorphism might contribute to the susceptibility of cancers especially in the Asian population and for colorectal cancer.

Cited by 6 publications

References 0 publications

DNMT1 , DNMT3A and DNMT3B Polymorphisms Associated With Gastric Cancer Risk: A Systematic Review and Meta-analysis

DNMT1 , DNMT3A and DNMT3B Polymorphisms Associated With Gastric Cancer Risk: A Systematic Review and Meta-analysis

DNMT3B Functions: Novel Insights From Human Disease

Investigation of the DNMT3B –579 G>T Promoter Polymorphism in Patients with Colorectal Cancer in an Azerbaijani Population

Contact Info

Product

Resources

About